Relevium Technologies Inc.

Relevium Technologies Inc. engages in the identification, evaluation, acquisition, and operation of brands and businesses in the health and wellness markets with a focus on e-commerce. The company markets dietary supplements, nutraceuticals, sports nutrition products, and cosmeceuticals primarily through its Bioganix brand portfolio online; dietary supplements under the LeefyLyfe brand name; and skin care products under the Push & Pull System brand. It also provides Relevium Senior, a geriatric brand targeting inflammatory conditions, including joints, heart, and brain; and Relevium Kids, a pediatric brand of nutraceuticals and oral nutritional supplements. The company was formerly known as BIOflex Technologies Inc. and changed its name to Relevium Technologies Inc. in December 2015. Relevium Technologies Inc. is headquartered in Montreal, Canada.

Relevium Technologies Inc. trades as RLLVF on OTC. The company is classified in Healthcare / Medical - Pharmaceuticals and reports in USD.

The current profile places the business in Medical - Pharmaceuticals. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $913,644 of revenue and -$5.37M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Relevium Technologies Inc. can be compared against peers such as BICO Group AB (publ), BrainsWay Ltd., BICO Group AB (publ), CYBERDYNE Inc., CYBERDYNE Inc., Genfit S.A..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $1.98M, beta of 2.51, and return on equity of +109.5%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

RLLVF currently shows total debt of $3.20M and beta of 2.51. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.releviumtechnologies.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.